Nanomedicine - Global Developments and Growth Opportunities

Potential for Targeted Therapeutic Action Boosts Popularity of Nanomedicine

With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters. At the same time, the adoption of nanotechnology-based applications by large therapeutic and diagnostic companies is accelerating the development of nanomedicine.

The prospect of site-specific therapeutic action and by extension of fewer side effects means that nanomedical applications have an enhanced risk-benefit analysis ratio. This is motivating their growing popularity as a therapeutic option.

"Furthermore, with techniques for early diagnosis of diseases and, in some cases, their disposition, prophylactic (preventive) intervention could well become a reality with the advent of nanomedicine," notes Rajaram Sankaran, Analyst from Frost & Sullivan (http://technicalinsights.frost.com). "With such prophylactic interventions, it might be possible to postpone or even completely avoid diseases, in some instances."

Key to nanomedicine's rapid evolution has been the embrace of nanotechnology-based applications by pharmaceuticals, biopharmaceuticals and drug delivery companies. Prominent instances include the use of Elan Corporation's NanoCrystal technology by Wyeth and Merck and the deployment of Quantum Dot Corporation's Qdot(r) particles by Pfizer, GSK, Astra Zeneca and Genentech.

Apart from such encouraging trends in the commercial sector, academia also has been instrumental in promoting the growth of nanomedicine. Innovation has been the leitmotif even as industry-academia partnerships have daily expanded the frontiers of nanomedical research.

However, while nanotechnology holds the promise of transforming the medical field, several challenges still remain. One of the most immediate issues confronting pure-play nanomedicine companies is the need to develop expertise across a range of technologies.

Forming synergistic collaborations with drug and medical device companies represents one of the most obvious routes of achieving such multi-disciplinary proficiency. Initially, such partnerships could take the form of joint marketing efforts, paving the way for nanomedical companies to independently handle all stages from R&D to commercialisation, in the long run.

Another important concern in the nanomedical arena has been the question of scalability - the ability to cost-effectively manufacture three-dimensional nano-structures in large-scale quantities. This challenge is rooted in the current lack of appropriate manufacturing standards for nanotechnology materials and components.

"There is a pressing need for standardised manufacturing techniques for nanotechnology-based components," cautions Mr. Sankaran. "This is especially required if nanotechnology-based applications need to graduate to the big league and become ubiquitous in everyday applications. While they have the potential, an appropriate set of standards would help them reach there."

At the same time, the unique characteristics of nano-scale matter also demand appropriate quality-control measures. The implementation of comprehensive manufacturing standards and quality-control measures is expected to be central to the sustained growth of nanomedicine.

(19/7/04)

--------------------------   More.................

Nanotechnology Industry Impact Research Service


Nanobiotech: Exploring New Frontiers in Medicine and Biotechnology

London, UK - August 28, 2003



Nanotechnolgy and biotechnology/medicine are interacting in a number of surprising and inventive ways to create an exciting new discipline - nanobiotechnology. From earlier, simpler disease detection, improved imaging, and rapid assessment of potential drug candidates to optimal drug delivery, nanobiotech is brimming with exhilarating possibilities.

"Besides facilitating detection of minutest traces of diseases such as cancer - or perhaps detecting a single spore of pathogen - nanostructured materials and nanodevices could provide better diagnosis of complex diseases and enable unprecedented drug delivery," says Technical Insight Analyst (www.technical-insights.frost.com), Girish Solanki.

He adds, "with a new generation of nanochips we could obtain much more accurate medical diagnosis; quickly and efficiently screen the mind boggling array of drug candidates and perform targeted delivery of drugs and vaccines like never before."

Forecasts suggest that nano-enabled services could potentially represent up to $180 billion annually in medicine and healthcare by 2015. Investments in a few biomedical nanotechnology firms appear to mirror the upbeat sentiment: at $10 million or more each, these exceed those for firms in many other nanotechnology sectors.

There has been significant progress in other areas too: novel nanostructured materials that serve as templates for tissue replacement and enable better treatment of burns and bone replacement have been developed. While this has certainly reduced the incidence of burn related fatalities, researchers are still in the early stages of their attempt to induce bone tissue growth through polymer templates.

In terms of drug delivery, developments in nanoencapsulation offer the promise of enhanced delivery and absorption. Here, the relatively inert nanocapsule adheres to and releases the drug solely at the target tissue site, thereby obviating toxicity concerns. Immune reactions associated with the use of modified viruses as the vector of gene-delivery, have trained the spotlight on carbon nanotubes, which now being contemplated as a system for drug delivery in gene therapy.

Additionally, researchers are contemplating the possibility of using magnetic nanoparticles containing drugs to be delivered to specific parts of the body by means of a magnetic field. This is likely to boost therapeutic benefit while minimising side effects on other parts of the body.

Similarly, there have been encouraging advancements in microfluidics, which enable modification of drug levels within the body in real time, thereby avoiding fluctuations in drug concentration. Electrospun fibre bandages that provide an attractive alternative to traditional gauze and elastic bandages are also being researched. These new bandages, created out of flannel-like material, staunch bleeding instantly and can be left in situ since they are absorbed by the body.

Nanotech is also likely to enhance biomolecular-imaging applications. On the one hand, researchers are focusing on ways to use AFM on organic materials so as to minimally impact the organic material as well as swiftly and accurately scan the materials in vivo. On the other hand, non-invasive imaging technologies such as diffusion tensor magnetic resonance imaging (DT-MRI) are likely to allow doctors to better detect development, degeneration, disease and ageing in soft tissue based on the generation of detailed images of the soft tissue's structure.

In addition to nanosensors being used to detect DNA sequences in the body, implanted nanosensors could enable simpler and more effective diagnosis. For instance, implanted devices could dispatch a signal to a pump to release more insulin for diabetes patients. Similar devices could be extended, over time, to deliver a wider range of medication.

Also, quantum dots, which have an ability to bond chemically to biological molecules and emit bright, fluorescent light, could be particularly effective early carcinoma-detection agents. "As a promising barcoding technology that can encode genes and proteins, quantum dots could potentially be employed to enhance the sensitivity of diagnostic tests for molecules that are hard to detect, such as those in cancer cells, or even the AIDS or hepatitis viruses," explains Mr. Solanki. 

Signs are now emerging that frenetic R&D activity in nanobiotech could lead to real devices that will edge out unwieldy lab-based procedures with economical, accurate microchips in the near term. 



(1/9/03)